BR0312030A - Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii - Google Patents
Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina iiInfo
- Publication number
- BR0312030A BR0312030A BR0312030-9A BR0312030A BR0312030A BR 0312030 A BR0312030 A BR 0312030A BR 0312030 A BR0312030 A BR 0312030A BR 0312030 A BR0312030 A BR 0312030A
- Authority
- BR
- Brazil
- Prior art keywords
- angiotensin
- combination
- receptor antagonists
- pde5 inhibitors
- pde5
- Prior art date
Links
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 abstract 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 101150098694 PDE5A gene Proteins 0.000 abstract 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0214784.1A GB0214784D0 (en) | 2002-06-26 | 2002-06-26 | Novel combination |
| PCT/IB2003/002657 WO2004002461A2 (en) | 2002-06-26 | 2003-06-16 | Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0312030A true BR0312030A (pt) | 2005-03-22 |
Family
ID=9939342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0312030-9A BR0312030A (pt) | 2002-06-26 | 2003-06-16 | Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1524996A2 (https=) |
| JP (1) | JP2005531627A (https=) |
| KR (1) | KR20050013156A (https=) |
| CN (1) | CN1662257A (https=) |
| AR (1) | AR040337A1 (https=) |
| AU (1) | AU2003242895A1 (https=) |
| BR (1) | BR0312030A (https=) |
| CA (1) | CA2491002A1 (https=) |
| GB (1) | GB0214784D0 (https=) |
| GT (1) | GT200300124A (https=) |
| MX (1) | MXPA04012569A (https=) |
| NO (1) | NO20050400L (https=) |
| PA (1) | PA8575501A1 (https=) |
| PE (1) | PE20040868A1 (https=) |
| PL (1) | PL375079A1 (https=) |
| RU (1) | RU2004136276A (https=) |
| TW (1) | TW200404546A (https=) |
| UY (1) | UY27863A1 (https=) |
| WO (1) | WO2004002461A2 (https=) |
| ZA (1) | ZA200409532B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| EP2433555A3 (en) * | 2002-07-26 | 2013-01-16 | Olympus Corporation | Image processing system |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| BRPI0502411A (pt) * | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
| ES2376628T3 (es) | 2005-06-10 | 2012-03-15 | Dong-A Pharmaceutical Co., Ltd. | Agente para la prevención y el tratamiento de las enfermedades hep�?ticas que contiene un dirivado pirazolopirimidina. |
| WO2007010337A2 (de) * | 2005-07-15 | 2007-01-25 | Proxomed Medizintechnik Gmbh | Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben |
| EP1940389A2 (en) * | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US7858611B2 (en) | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| AU2007249399A1 (en) * | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| RU2345763C1 (ru) * | 2007-04-26 | 2009-02-10 | ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию" | Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US6362178B1 (en) * | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| AP2002002455A0 (en) * | 1999-10-11 | 2002-06-30 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors. |
| WO2002013798A2 (en) * | 2000-08-11 | 2002-02-21 | Pfizer Limited | Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
-
2002
- 2002-06-26 GB GBGB0214784.1A patent/GB0214784D0/en not_active Ceased
-
2003
- 2003-06-04 GT GT200300124A patent/GT200300124A/es unknown
- 2003-06-13 PA PA20038575501A patent/PA8575501A1/es unknown
- 2003-06-16 MX MXPA04012569A patent/MXPA04012569A/es unknown
- 2003-06-16 KR KR10-2004-7021041A patent/KR20050013156A/ko not_active Ceased
- 2003-06-16 RU RU2004136276/15A patent/RU2004136276A/ru not_active Application Discontinuation
- 2003-06-16 CN CN03814574XA patent/CN1662257A/zh active Pending
- 2003-06-16 WO PCT/IB2003/002657 patent/WO2004002461A2/en not_active Ceased
- 2003-06-16 JP JP2004517093A patent/JP2005531627A/ja not_active Withdrawn
- 2003-06-16 PL PL03375079A patent/PL375079A1/xx not_active Application Discontinuation
- 2003-06-16 CA CA002491002A patent/CA2491002A1/en not_active Abandoned
- 2003-06-16 BR BR0312030-9A patent/BR0312030A/pt not_active IP Right Cessation
- 2003-06-16 EP EP03761725A patent/EP1524996A2/en not_active Withdrawn
- 2003-06-16 AU AU2003242895A patent/AU2003242895A1/en not_active Abandoned
- 2003-06-20 TW TW092116851A patent/TW200404546A/zh unknown
- 2003-06-24 PE PE2003000636A patent/PE20040868A1/es not_active Application Discontinuation
- 2003-06-24 AR ARP030102252A patent/AR040337A1/es not_active Application Discontinuation
- 2003-06-24 UY UY27863A patent/UY27863A1/es not_active Application Discontinuation
-
2004
- 2004-11-25 ZA ZA200409532A patent/ZA200409532B/en unknown
-
2005
- 2005-01-25 NO NO20050400A patent/NO20050400L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200409532B (en) | 2006-06-28 |
| CN1662257A (zh) | 2005-08-31 |
| PE20040868A1 (es) | 2004-11-25 |
| MXPA04012569A (es) | 2005-04-19 |
| AU2003242895A1 (en) | 2004-01-19 |
| RU2004136276A (ru) | 2005-09-10 |
| KR20050013156A (ko) | 2005-02-02 |
| JP2005531627A (ja) | 2005-10-20 |
| AR040337A1 (es) | 2005-03-30 |
| GT200300124A (es) | 2004-03-17 |
| NO20050400L (no) | 2005-03-29 |
| WO2004002461A3 (en) | 2004-05-13 |
| GB0214784D0 (en) | 2002-08-07 |
| EP1524996A2 (en) | 2005-04-27 |
| PL375079A1 (en) | 2005-11-14 |
| PA8575501A1 (es) | 2003-12-30 |
| UY27863A1 (es) | 2003-12-31 |
| WO2004002461A2 (en) | 2004-01-08 |
| TW200404546A (en) | 2004-04-01 |
| CA2491002A1 (en) | 2004-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE346070T1 (de) | Purinderivate als kinaseinhibitoren | |
| CY1105390T1 (el) | Θepαπευτικη αγωγη της πνευμονικης υπερτασης | |
| BR0314196A (pt) | Inibidores de tgf-beta | |
| BR0312030A (pt) | Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii | |
| MX2007002311A (es) | Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos. | |
| DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| SV2002000287A (es) | Uso de inhibidor de la quinasa dependiente de la ciclina para preparar una composicion farmaceutica util para tratar enfermedades neurodegenerativas | |
| NO20076554L (no) | Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer | |
| CY1117108T1 (el) | Ιμιδαζοτριαζινες και ιμιδαζοπυριμιδινες ως αναστολeiς κινασης | |
| NI201000059A (es) | Inhibidores de la cinasa c-fms. | |
| IL163777A0 (en) | Kinase inhibitors | |
| BRPI0412894A (pt) | tienopiridina e furopiridina inibidores de quinases | |
| UY30297A1 (es) | Inhibidores de la quinasa c-fms-i | |
| BR0317284A (pt) | Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno | |
| BR0311191A (pt) | Combinação | |
| GT200300231A (es) | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso | |
| BR0307595A (pt) | Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico | |
| EP1496897A4 (en) | Tyrosine kinase inhibitor | |
| ATE390425T1 (de) | Xanthin-phosphodiesterase-v-hemmer polymorphe | |
| EA200401137A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
| SE0302331D0 (sv) | New use II | |
| DOP2003000649A (es) | Nueva combinacion | |
| NO20065850L (no) | Fremgangsmate for identifisering av PDE5-modulatorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |